Power Law company profile

Amicus Therapeutics

Biotech & Life Sciences · Philadelphia, United States · Founded 2002 · IPO 2007 Unicorn

Discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases

Valuation

$4.70B

Market cap · May/2026

Revenue

$634M

Latest reported FY

EBITDA

$144M

Latest reported FY

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026 $10B+ revenueThoroughbred · Power Law outcome

Investors

9 investors on Amicus Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage

CHL Medical Partners

Series B+ 8 investors entered at this stage

Prospect Venture Partners

Palo Alto Investors

Prospect Venture Partners

NEA

Quaker Bio Ventures

Canaan

Radius Ventures

Frazier Healthcare Partners

Global footprint

Where Amicus Therapeutics has talent and traffic

AI talent share

0.2% of workforce is AI talent
(1 of 629 staff)

Core AI00%

Other AI10.16%

Non-AI workforce62899.84%

Workforce by country

21 countries with
team presence

🇺🇸 United States54.4%

🇬🇧 United Kingdom19.4%

🇩🇪 Germany4.6%

🇮🇪 Ireland4.3%

🇯🇵 Japan3.8%

Top 5 of 21 shown

Web traffic by country

22K monthly visits
across markets

🇺🇸 United States53.2%

🇮🇳 India15.9%

🇬🇧 United Kingdom10%

🇨🇦 Canada8.6%

🇯🇵 Japan5%

Top 5 markets shown

Patent intelligence

$164M patent portfolio · 101 active families

Estimated portfolio value

$164M

3.5% of market cap · 1.6× the top peer Horizon Therapeutics ($100M)

101 active patent families

Where Amicus Therapeutics innovates PharmacologyMolecular biologyDiseasePharmacological chaperonePharmaceutical drug

Where Amicus Therapeutics concentrates vs peers

Each axis is a top-10 topic across Amicus Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Amicus Therapeutics

An AI-synthesized read of the highest-engagement posts about Amicus Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Amicus Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles